Robert LeBoyer

Stock Analyst at Noble Capital Markets

(2.17)
# 2,723
Out of 4,893 analysts
18
Total ratings
43.75%
Success rate
9.07%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $42.36
Upside: +65.25%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $8.20
Upside: +58.54%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6$10
Current: $0.67
Upside: +1,399.48%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $5.25
Upside: +1,042.86%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $13.00
Upside: +361.54%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.45
Upside: +189.86%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.93
Upside: +625.39%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.02
Upside: +684.31%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.35
Upside: +34,088.03%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $13.80
Upside: -
Initiates: Buy
Price Target: $12
Current: $11.18
Upside: +7.33%
Initiates: Buy
Price Target: $825,000
Current: $0.91
Upside: +90,908,990.91%
Downgrades: Neutral
Price Target: n/a
Current: $17.55
Upside: -
Initiates: Buy
Price Target: $15
Current: $3.97
Upside: +277.83%